|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2005-11-21
|
|
pubmed:abstractText |
Primary central nervous system (CNS) tumors represent a diverse group of tumor types with heterogeneous molecular mechanisms that underlie their formation and maintenance. CNS tumors depend on angiogenesis and often display increased activity of ErbB-associated pathways. Current nonspecific therapies frequently have poor efficacy in many of these tumor types, so there is a pressing need for the development of novel targeted therapies.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BignerDarell DDD,
pubmed-author:DimeryIsaiahI,
pubmed-author:FriedmanHenry SHS,
pubmed-author:GranerMichael WMW,
pubmed-author:KaipainenArjaA,
pubmed-author:KeirStephen TST,
pubmed-author:KieranMark WMW,
pubmed-author:LaformeAndreaA,
pubmed-author:McLendonRoger ERE,
pubmed-author:RasheedB K AhmedBK,
pubmed-author:ReardonDavid ADA,
pubmed-author:RichJeremy NJN,
pubmed-author:RyanAnderson JAJ,
pubmed-author:SathornsumeteeSithS,
pubmed-author:WangLingL,
pubmed-author:WheelerCatherineC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
8145-57
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16299247-Animals,
pubmed-meshheading:16299247-Cell Line, Tumor,
pubmed-meshheading:16299247-Cell Movement,
pubmed-meshheading:16299247-Cell Proliferation,
pubmed-meshheading:16299247-Central Nervous System Neoplasms,
pubmed-meshheading:16299247-Dose-Response Relationship, Drug,
pubmed-meshheading:16299247-Ependymoma,
pubmed-meshheading:16299247-Glioma,
pubmed-meshheading:16299247-Humans,
pubmed-meshheading:16299247-Immunohistochemistry,
pubmed-meshheading:16299247-Ki-67 Antigen,
pubmed-meshheading:16299247-Mice,
pubmed-meshheading:16299247-Mice, Nude,
pubmed-meshheading:16299247-Mitogen-Activated Protein Kinase 1,
pubmed-meshheading:16299247-Mitogen-Activated Protein Kinase 3,
pubmed-meshheading:16299247-Neovascularization, Pathologic,
pubmed-meshheading:16299247-Phosphorylation,
pubmed-meshheading:16299247-Piperidines,
pubmed-meshheading:16299247-Quinazolines,
pubmed-meshheading:16299247-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16299247-Receptors, Vascular Endothelial Growth Factor,
pubmed-meshheading:16299247-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
|
|
pubmed:affiliation |
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. rich0001@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
